Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 3/20 | 0.66 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.56 |
| ▸ | ACVR1 | Q04771 | 8/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3108242 | 0.90 | CSNK1D (0.71) | CSNK1DMAPK14ACVR1MAPK13MAPK12 | |
| SCHEMBL3112056 | 0.86 | MAPK14 (0.51) | CSNK1DMAPK14ACVR1MAPK13MAPK12 | |
| SCHEMBL10290480 | 0.85 | CSNK1D (0.75) | CSNK1DMAPK14ACVR1MAPK13MAPK12 | |
| SCHEMBL10290479 | 0.84 | CSNK1D (0.71) | CSNK1DMAPK14ACVR1MAPK13MAPK12 | |
| SCHEMBL3096765 | 0.84 | MAPK14 (0.50) | CSNK1DMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3091618 | 0.81 | CSNK1D (0.93) | CSNK1DMAPK14ACVR1MAPK13MAPK12 | |
| SCHEMBL3094899 | 0.81 | ACVR1 (0.58) | CSNK1DMAPK14ACVR1MAPK13MAPK12 | |
| SCHEMBL10290481 | 0.79 | CSNK1D (0.90) | CSNK1DMAPK14ACVR1MAPK13MAPK12 | |
| SCHEMBL10290484 | 0.79 | CSNK1D (0.66) | CSNK1DMAPK14ACVR1MAPK13MAPK12 | |
| SCHEMBL3095762 | 0.77 | MAPK14 (0.44) | CSNK1DMAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217600-B1 | FUNGICIDAL BICYCLIC PYRAZOLES | DU PONT (US) | 2012-12-05 | — | — | EP | claimed |
| US-8288375-B2 | Fungicidal bicyclic pyrazoles | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-10-16 | — | — | US | claimed |
| US-20100273775-A1 | FUNGICIDAL BICYCLIC PYRAZOLES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-10-28 | — | — | US | claimed |
| EP-2217600-A2 | FUNGICIDAL BICYCLIC PYRAZOLES | E. I. du Pont de Nemours and Company (US) | 2010-08-18 | — | — | EP | claimed |
| WO-2009076440-A2 | FUNGICIDAL BICYCLIC PYRAZOLES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-06-18 | — | — | WO | claimed |
| EP-2217600-B1 | FUNGICIDAL BICYCLIC PYRAZOLES | DU PONT (US) | 2012-12-05 | — | — | EP | disclosed |
| US-8288375-B2 | Fungicidal bicyclic pyrazoles | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2409570-A2 | Fungicidal mixtures based on pyrazolopyridine compounds | BASF SE (DE) | 2012-01-25 | — | — | EP | disclosed |
| CN-101889012-A | Fungicidal bicyclic pyrazoles | DU PONT | 2010-11-17 | — | — | CN | disclosed |
| US-20100273775-A1 | FUNGICIDAL BICYCLIC PYRAZOLES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-10-28 | — | — | US | disclosed |
| EP-2217600-A2 | FUNGICIDAL BICYCLIC PYRAZOLES | E. I. du Pont de Nemours and Company (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009076440-A2 | FUNGICIDAL BICYCLIC PYRAZOLES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273775-A1 | FUNGICIDAL BICYCLIC PYRAZOLES | CYP1B1, CBR1, CYP1A1 | CSNK1D 1670/4885MAPK14 3609/4885ACVR1 3435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.